Technology transfer agreements under which he irrevocably transferred to us his intellectual property rights in the PharmacoSurgery platform and former Chondroprotective program, with a repurchase right on certain liquidations.
| Officer | Age | In this role | Joined | Source |
|---|---|---|---|---|
|
Gregory A. Demopulos
Also a director
President, Chief Executive Officer and Chairman of the Board of Directors
|
67 |
Since 1994
32 years
|
Not stated | |
|
David J. Borges
Vice President, Finance, Chief Accounting Officer and Treasurer
|
62 |
Since 2024
2 years
|
2020 | |
|
Peter B. Cancelmo
Vice President, General Counsel and Secretary
|
47 |
Since 2019
7 years
|
2019 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 30, 2026 · updated by the 8-K of Aug 13, 2026
| Director | Age | On board | Independent | Committees | Other public boards | Pay | Source |
|---|---|---|---|---|---|---|---|
|
Gregory A. Demopulos, M.D.
CEO, Board chair
|
67 |
1994
32 years
|
Not independent | None stated | Smead Funds Trust | Paid as CEO | |
|
Thomas J. Cable
Lead independent director
|
86 |
1995
31 years
|
Independent |
Nominating and Governance · Chair
|
None stated | Not stated | |
|
Peter A. Demopulos, M.D.
|
72 |
1995
31 years
|
Not independent |
Scientific
|
None stated | Not stated | |
|
Diana T. Perkinson, M.D.
|
72 |
2023
3 years
|
Independent |
Scientific
|
None stated | Not stated | |
|
Thomas F. Bumol, Ph.D.
|
72 |
2019
7 years
|
Independent |
Scientific · Chair
|
None stated | Not stated | |
|
Leroy E. Hood, M.D., Ph.D.
|
87 |
2001
25 years
|
Independent |
Compensation
|
None stated | Not stated | |
|
Arnold C. Hanish
|
78 |
2012
14 years
|
Independent |
Audit · Chair
|
None stated | Not stated | |
|
Rajiv Shah, M.D.
|
53 |
2015
11 years
|
Independent |
Audit
Compensation
Scientific
|
None stated | Not stated | |
|
Joseph Schocken
Joined Aug 12, 2026
|
- | - | - |
Audit Committee
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Technology transfer agreements under which he irrevocably transferred to us his intellectual property rights in the PharmacoSurgery platform and former Chondroprotective program, with a repurchase right on certain liquidations.
Indemnification agreements providing for indemnification of expenses, judgments, fines and settlements relating to their service to the company.
Loading...